Benitec Biopharma (BNTC) news
Recent news
Benitec Biopharma Inc - Timelines for BB-301 pivotal study remain on track
Benitec Biopharma Inc. (NASDAQ: BNTC) continues to advance its BB-301 gene therapy program for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD) with dysphagia, with timelines for the pivotal study remaining on track. The company has reported positive interim clinical results from its…
AInvest Wire · Oct 5, 2026Benitec Biopharma - Patient enrollment for BB-301 pivotal study planned to begin in mid-2027
AInvest Wire · Oct 5, 2026Benitec Biopharma - FDA requests additional data for BB-301 pivotal study including opmd natural history study data
AInvest Wire · Oct 5, 2026Benitec Biopharma - Final BB-301 pivotal study design expected to be confirmed in 1Q 2027
AInvest Wire · Oct 5, 2026Benitec Biopharma - May offer securities up to $200 mln - SEC filing
Benitec Biopharma Inc. has filed with the U.S. Securities and Exchange Commission (SEC) to offer and sell up to $200 million in securities, according to a recent filing [1]. The offering, which has not yet commenced, is subject to market conditions and regulatory approval. The company did not…
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.